Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50

Benzinga · 1d ago
Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.